Skip to main content

Table 3 Comparisons of HAQ, BASFI, and NHP by age groups

From: Assessment of physical function, quality of life, and medication adherence in elderly patients with rheumatic diseases

 

18–64 years (group 1)

≥ 65 years (group 2)

Total

P*

 

Mean

Median

Mean

Median

Mean

Median

HAQ

0.21 ± 0.237

0.15 (0–1)

0.46 ± 0.883

0.3 (0–7)

0.37 ± 0.722

0.2 (0–7)

0.003

BASFI

1.91 ± 1.798

1.7 (0.1–7.2)

4.8 ± 0.957

4.9 (3.4–6.1)

2.35 ± 1.988

1.8 (0.1–7.2)

0.001

NHP pain

21.367 ± 27.337

12.91 (0–100)

41.544 ± 32.118

29.4 (0–100)

31.688 ± 31.463

18.74 (0–100)

0.000

NHP emotional reaction

11.853 ± 18.063

0 (0–76.25)

22.072 ± 24.905

16.21 (0–86.25)

17.08± 22.364

7.15 (0–86.25)

0.005

NHP sleep

20.728 ± 29.303

0 (0–87.63)

42.525 ± 39.075

43.36 (0–100)

31.877 ± 36.235

12.57 (0–100)

0.000

NHP social isolation

10.829 ± 15.836

0 (0–81.64)

19.416 ± 27.905

0 (0–100)

15.221 ± 23.16

0 (0–100)

0.062

NHPphysical activity

16.78 ± 23.827

10.57 (0–88.7)

35.025 ± 25.441

42.1 (0–88.7)

26.112 ± 26.24

11.2 (0–88.7)

0.000

NHP energy

23.708 ± 33.106

0 (0–100)

36.164 ± 38.408

24 (0–100)

30.079 ± 36.353

24 (0–100)

0.024

MARS

17.2 ± 4.954

18 (5–25)

14.787 ± 5.546

16 (5–25)

15.966 ± 5.388

17 (5–25)

0.004

  1. P ≤ 0.05 HAQ Health Assessment Questionnaire, BASFI Bath Ankylosing Spondylitis Functional Index, NHP Nottingham Health Profile, MARS Medication Adherence Rating Scale
  2. *Mann-Whitney U test
  3. P ≤ 0.05 is considered significant